Clinical utilization of olaparib, a PARP inhibitor, in <i>BRCA1</i>-mutant metastatic acral melanoma

Ruixin Jiang; Xianbin Liang; Ye Tao; Ronghui Xia; Ming Lei; Bin Jiang; Robert L. Judson-Torres; Yanjie Zhang; Weizhen Zhang; Hanlin Zeng

doi:10.1016/j.gendis.2022.11.014

| Sign up

PDF (1.2 MB)

Cite

EndNote(RIS) BibTeX

Collect

Submit Manuscript

Show Outline

Outline

References

Show full outline

Hide outline

Rapid Communication | Open Access

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma

Ruixin Jiang^{^a^,^c^,¹}, Xianbin Liang^{^b^,¹}, Ye Tao^{^a^,^c}, Ronghui Xia^{^d}, Ming Lei^{^c}, Bin Jiang^{^a}, Robert L. Judson-Torres^{^e^,^f}, Yanjie Zhang^{^a^,^c}(), Weizhen Zhang^{^b}(), Hanlin Zeng^{^a^,^c}()

Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China

Department of Oncology, The Third People's Hospital of Zhengzhou; Zhengzhou, Henan 450000, China

Shanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China

Department of Oral & Maxillofacial - Head and Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China

Department of Dermatology, University of Utah, Salt Lake City, UT 84132, USA

Huntsman Cancer Institute, Salt Lake City, UT 84112, USA

¹ Co-first authors.

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175-180.

Crossref Google Scholar

Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst. 2019;111(10):1068-1077.

Crossref Google Scholar

Byeon S, Cho HJ, Jang KT, et al. Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. ESMO Open. 2021;6(1):100002.

Crossref Google Scholar

U.S. Food & Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed December 1, 2021. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.

Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345-358.

Crossref Google Scholar

Genes & Diseases

Volume 10 Issue 5,
September 2023

Pages 1755-1758

DOI: 10.1016/j.gendis.2022.11.014

Cite this article:

Jiang R, Liang X, Tao Y, et al. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma. Genes & Diseases, 2023, 10(5): 1755-1758. https://doi.org/10.1016/j.gendis.2022.11.014